Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)

2026-03-21 - 12:33

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted therapy In addition to improvement in PFS, ZEGFROVY® also showed superior results in all